Life Technologies aims to be companion Dx "partner of choice" with Compendia acquisition
This article was originally published in Clinica
Executive Summary
Genome sequencing firm Life Technologies has acquired cancer bioinformatics specialist Compendia Bioscience in a deal that will expand its abilities to develop its own tests and to partner with pharma companies for the development of companion diagnostics. Financial terms were not disclosed.